NASDAQ:CDXC - ChromaDex Stock Price, Price Target & More

$3.95 -0.04 (-1.00 %)
(As of 04/25/2018 02:18 PM ET)
Previous Close$3.99
Today's Range$3.90 - $4.04
52-Week Range$2.32 - $7.24
Volume176,234 shs
Average Volume448,522 shs
Market Capitalization$232.51 million
P/E Ratio-11.30
Dividend YieldN/A
Beta1.03

About ChromaDex (NASDAQ:CDXC)

ChromaDex logoChromaDex Corporation, a natural products company, discovers, acquires, develops, and commercializes patented and proprietary ingredient technologies. The company offers bulk raw materials for use in dietary supplements, food, beverages, and cosmetic products; Nicotinamide riboside (NIAGEN), a vitamin found naturally in milk for enhancing cardiovascular health, glucose levels, cognitive function, and anti-aging effects; Pterostilbene (pTeroPure), a polyphenol and antioxidant used in health related fields; and Immulina, a spirulina extract and compound, which is used for improving human immune function, as well as developing Pterostilbene and caffeine co-crystal ingredients, and anthocyanins ingredients. It also provides reference standards, materials, and kits to conduct quality control of raw materials and consumer products; and fine chemicals and phytochemicals for research and new product development applications. In addition, the company offers a range of contract services, including routine contract analysis for the production of dietary supplements, cosmetics, foods, and other natural products, as well as elaborate contract research for clients in these industries; and consulting services in the areas of regulatory support, new ingredient or product development, risk management, and litigation support, as well as product regulatory approval and scientific advisory services. Further, it assists customers in creating processes for manufacturing of natural products using green chemistry, as well as developing quality verification seal program, phytochemical libraries, plant extracts libraries, and databases for cross-referencing phytochemicals. The company markets and sells its products directly in the United States and Canada; and through distributors in Europe, China, Japan, South Korea, Brazil, Australia, New Zealand, Taiwan, South Africa, India, Indonesia, Malaysia, Singapore, Thailand, and Mexico. ChromaDex Corporation is based in Irvine, California.

Receive CDXC News and Ratings via Email

Sign-up to receive the latest news and ratings for CDXC and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Medicinals & botanicals
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:CDXC
CUSIPN/A
Phone949-419-0288

Debt

Debt-to-Equity Ratio0.01%
Current Ratio7.08%
Quick Ratio6.36%

Price-To-Earnings

Trailing P/E Ratio-11.30
Forward P/E Ratio-28.21
P/E GrowthN/A

Sales & Book Value

Annual Sales$21.20 million
Price / Sales10.22
Cash FlowN/A
Price / CashN/A
Book Value$1.00 per share
Price / Book3.95

Profitability

EPS (Most Recent Fiscal Year)($0.35)
Net Income$-11,370,000.00
Net Margins-48.68%
Return on Equity-52.15%
Return on Assets-40.36%

Miscellaneous

Employees74
Outstanding Shares54,840,000

How to Become a New Pot Stock Millionaire

ChromaDex (NASDAQ:CDXC) Frequently Asked Questions

What is ChromaDex's stock symbol?

ChromaDex trades on the NASDAQ under the ticker symbol "CDXC."

How were ChromaDex's earnings last quarter?

ChromaDex (NASDAQ:CDXC) issued its quarterly earnings results on Thursday, March, 8th. The company reported ($0.17) EPS for the quarter, meeting the consensus estimate of ($0.17). The company had revenue of $7.53 million for the quarter, compared to the consensus estimate of $7.50 million. ChromaDex had a negative net margin of 48.68% and a negative return on equity of 52.15%. View ChromaDex's Earnings History.

When is ChromaDex's next earnings date?

ChromaDex is scheduled to release their next quarterly earnings announcement on Thursday, May, 10th 2018. View Earnings Estimates for ChromaDex.

What price target have analysts set for CDXC?

2 brokers have issued 12 month price targets for ChromaDex's stock. Their predictions range from $7.00 to $8.00. On average, they expect ChromaDex's share price to reach $7.50 in the next twelve months. View Analyst Ratings for ChromaDex.

What are Wall Street analysts saying about ChromaDex stock?

Here are some recent quotes from research analysts about ChromaDex stock:
  • 1. According to Zacks Investment Research, "ChromaDex Corporation and its subsidiaries supply phytochemical reference standards and reference materials, related contract services, and products for the dietary supplement, nutraceutical, food and beverage, functional food, pharmaceutical and cosmetic markets. ChromaDex's core business strategy is to use the intellectual property harnessed by its expertise in the area of natural products and in the creation of reference materials to the industry as the basis for providing new and alternative, green, mass marketable products to its customers. The Company's main priority is to create industry-accepted information, and to provide products and services to every layer of the functional food, pharmaceutical, personal care and dietary supplement markets. The company markets and sells its products in the United States and Canada. It offers its products through distributors in Europe, South America, Korea, India, Japan, Australia, New Zealand, China, Indonesia, Malaysia, Singapore, Thailand, and Mexico. " (4/17/2018)
  • 2. HC Wainwright analysts commented, "We note that the company’s revenues came in at $5.3M vs. our original forecast of $8M, while a net loss of $2.7M or $0.07 per share was also recorded vs. our projection for a positive EPS of $0.04. While R&D spending in the quarter was roughly in-line with our estimate at $728K vs. $700K, we note that COGS were slightly worse than our estimate, coming in at 57% vs. our projection of 49%. Given what we see as the current status of ChromaDex’s ingredients business, we have revised our 2017 revenue number to $24.3M, while we now project a net loss per share for 2017 of $0.14 vs. our prior forecast for EPS of $0.16 for the year." (8/11/2017)

Who are some of ChromaDex's key competitors?

Who are ChromaDex's key executives?

ChromaDex's management team includes the folowing people:
  • Mr. Frank Louis Jaksch Jr., Co-Founder, Chief Exec. Officer and Director (Age 50)
  • Mr. Robert N. Fried, Pres, Chief Strategy Officer, COO and Director (Age 58)
  • Mr. Thomas C. Varvaro, Consultant (Age 48)
  • Mr. Troy Allen Rhonemus, Exec. VP (Age 45)
  • Mr. Kevin M. Farr, Chief Financial Officer (Age 60)

Has ChromaDex been receiving favorable news coverage?

News articles about CDXC stock have been trending positive on Wednesday, according to Accern Sentiment Analysis. The research firm scores the sentiment of press coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. ChromaDex earned a media sentiment score of 0.44 on Accern's scale. They also gave headlines about the company an impact score of 47.82 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the near term.

How do I buy shares of ChromaDex?

Shares of CDXC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is ChromaDex's stock price today?

One share of CDXC stock can currently be purchased for approximately $3.95.

How big of a company is ChromaDex?

ChromaDex has a market capitalization of $232.51 million and generates $21.20 million in revenue each year. The company earns $-11,370,000.00 in net income (profit) each year or ($0.35) on an earnings per share basis. ChromaDex employs 74 workers across the globe.

How can I contact ChromaDex?

ChromaDex's mailing address is 10005 Muirlands Blvd. Suite G, IRVINE CA, 92618. The company can be reached via phone at 949-419-0288 or via email at [email protected]


MarketBeat Community Rating for ChromaDex (CDXC)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  127 (Vote Outperform)
Underperform Votes:  98 (Vote Underperform)
Total Votes:  225
MarketBeat's community ratings are surveys of what our community members think about ChromaDex and other stocks. Vote "Outperform" if you believe CDXC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CDXC will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

ChromaDex (NASDAQ:CDXC) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
2 Wall Street analysts have issued ratings and price targets for ChromaDex in the last 12 months. Their average twelve-month price target is $7.50, suggesting that the stock has a possible upside of 89.87%. The high price target for CDXC is $8.00 and the low price target for CDXC is $7.00. There are currently 2 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $7.50$7.50$7.50$6.3333
Price Target Upside: 89.87% upside55.28% upside32.74% upside47.29% upside

ChromaDex (NASDAQ:CDXC) Consensus Price Target History

Price Target History for ChromaDex (NASDAQ:CDXC)

ChromaDex (NASDAQ:CDXC) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/2/2018HC WainwrightSet Price TargetBuy$8.00HighView Rating Details
9/25/2017Ladenburg ThalmannInitiated CoverageBuy -> Buy$7.00N/AView Rating Details
1/3/2017Rodman & RenshawInitiated CoverageBuy$6.00N/AView Rating Details
(Data available from 4/25/2016 forward)

Earnings

ChromaDex (NASDAQ:CDXC) Earnings History and Estimates Chart

Earnings by Quarter for ChromaDex (NASDAQ:CDXC)

ChromaDex (NASDAQ:CDXC) Earnings Estimates

Current Year EPS Consensus Estimate: $-0.14 EPS
Next Year EPS Consensus Estimate: $0.02 EPS

ChromaDex (NASDAQ CDXC) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/9/2018($0.03)N/AView Earnings Details
3/8/2018Q4 2017($0.17)($0.17)$7.50 million$7.53 millionViewListenView Earnings Details
11/9/2017Q3 2017($0.05)($0.07)$6.50 million$6.09 millionViewN/AView Earnings Details
8/10/2017Q2 2017$0.04($0.05)$11.00 million$5.31 millionViewN/AView Earnings Details
5/11/2017Q1 2017$0.01($0.05)$8.00 million$4.45 millionViewN/AView Earnings Details
3/16/2017Q4 2016($0.01)($0.06)$5.60 million$5.64 millionViewN/AView Earnings Details
11/10/2016Q3 2016($0.03)$5.01 millionViewListenView Earnings Details
8/11/2016Q216$0.01$6.10 million$8.80 millionViewListenView Earnings Details
5/12/2016Q116$0.01$5.30 million$7.30 millionViewListenView Earnings Details
3/17/2016Q4 2015($0.03)$4.36 millionViewN/AView Earnings Details
5/14/2015Q1 2015($0.03)$5.26 millionViewN/AView Earnings Details
11/6/2014Q3 2014($0.03)$4.14 millionViewN/AView Earnings Details
8/12/2014Q2 2014($0.06)$3.86 millionViewN/AView Earnings Details
5/8/2014Q1 2014($0.06)$3.07 millionViewN/AView Earnings Details
11/21/2013Q3 13($0.01)$2.72 millionViewN/AView Earnings Details
8/13/2013Q2 2013($0.03)$2.71 millionViewN/AView Earnings Details
5/10/2013Q1 2013$0.03$2.34 millionViewN/AView Earnings Details
3/29/2013Q4 2012($0.06)ViewN/AView Earnings Details
11/8/2012Q3 2012($0.06)($0.06)ViewN/AView Earnings Details
8/9/2012Q2 2012($0.12)($0.13)ViewN/AView Earnings Details
5/10/2012Q1 2012($0.09)($0.16)ViewN/AView Earnings Details
3/15/2012Q4 2011($0.09)($0.10)ViewN/AView Earnings Details
11/10/2011Q3 2011($0.09)($0.10)ViewN/AView Earnings Details
8/11/2011Q2 2011($0.08)ViewN/AView Earnings Details
5/12/2011Q1 2011($0.05)ViewN/AView Earnings Details
3/16/2011Q4 2010($0.03)ViewN/AView Earnings Details
11/16/2010Q3 2010($0.03)ViewN/AView Earnings Details
8/17/2010Q2 2010($0.02)ViewN/AView Earnings Details
3/31/2010Q4 2009($0.01)ViewN/AView Earnings Details
11/17/2009Q3 2009($0.02)ViewN/AView Earnings Details
8/18/2009Q2 2009($0.03)ViewN/AView Earnings Details
5/15/2009Q1 2009($0.03)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

ChromaDex (NASDAQ:CDXC) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

ChromaDex (NASDAQ CDXC) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 11.59%
Institutional Ownership Percentage: 10.14%
Insider Trading History for ChromaDex (NASDAQ:CDXC)
Institutional Ownership by Quarter for ChromaDex (NASDAQ:CDXC)

ChromaDex (NASDAQ CDXC) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/29/2018Frank L Jaksch JrCEOSell474$4.60$2,180.40View SEC Filing  
3/27/2018Frank L Jaksch JrCEOSell24,578$4.60$113,058.80View SEC Filing  
1/11/2018Frank L Jaksch JrCEOSell28,379$6.52$185,031.08View SEC Filing  
12/21/2017Frank L Jaksch JrCEOSell58,400$6.19$361,496.00View SEC Filing  
11/17/2017River Ventures Ltd ChampionMajor ShareholderBuy731,707$4.10$2,999,998.70View SEC Filing  
8/25/2017Stephen R AllenDirectorBuy2,000$3.31$6,620.007,000View SEC Filing  
8/18/2017Step Holdings Ltd PioneerMajor ShareholderBuy786,167$2.60$2,044,034.20View SEC Filing  
8/15/2017Robert N FriedInsiderBuy10,000$3.15$31,500.00583,241View SEC Filing  
5/24/2017Step Holdings Ltd PioneerMajor ShareholderBuy2,521,526$2.60$6,555,967.60View SEC Filing  
5/19/2017Stephen R AllenDirectorBuy3,000$3.20$9,600.005,000View SEC Filing  
3/20/2017Stephen R AllenDirectorBuy2,000$2.81$5,620.002,000View SEC Filing  
12/12/2016Frank L Jaksch JrCEOBuy2,000$2.42$4,840.00201,557View SEC Filing  
9/1/2016Frank L Jaksch JrCEOBuy1,500$3.32$4,980.00199,557View SEC Filing  
9/1/2016Robert N FriedDirectorBuy15,000$3.39$50,850.0066,979View SEC Filing  
6/20/2016Troy Allen RhonemusCOOBuy7,800$3.47$27,066.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

ChromaDex (NASDAQ CDXC) News Headlines

Source:
DateHeadline
BRIEF-Chromadex Corp Appoints Rob Fried as Chief Executive OfficerBRIEF-Chromadex Corp Appoints Rob Fried as Chief Executive Officer
www.reuters.com - April 24 at 9:24 AM
ChromaDex Appoints Frank Jaksch As Executive Chairman, Rob Fried as Chief Executive Officer and Kurt Gustafson ...ChromaDex Appoints Frank Jaksch As Executive Chairman, Rob Fried as Chief Executive Officer and Kurt Gustafson ...
globenewswire.com - April 23 at 4:28 PM
ChromaDex Appoints Frank Jaksch As Executive Chairman, Rob Fried as Chief Executive Officer and Kurt Gustafson as Lead DirectorChromaDex Appoints Frank Jaksch As Executive Chairman, Rob Fried as Chief Executive Officer and Kurt Gustafson as Lead Director
finance.yahoo.com - April 23 at 4:28 PM
ChromaDex (CDXC) Stock Rating Upgraded by ValuEngineChromaDex (CDXC) Stock Rating Upgraded by ValuEngine
www.americanbankingnews.com - April 20 at 7:28 PM
ChromaDex (CDXC) versus USANA Health Sciences (USNA) Head-To-Head ContrastChromaDex (CDXC) versus USANA Health Sciences (USNA) Head-To-Head Contrast
www.americanbankingnews.com - April 20 at 1:26 AM
Pre-Market Technical Scan on Chemicals Equities -- Celanese, ChromaDex, Rayonier Advanced Materials, and ...Pre-Market Technical Scan on Chemicals Equities -- Celanese, ChromaDex, Rayonier Advanced Materials, and ...
www.prnewswire.com - April 18 at 9:26 AM
ChromaDex (CDXC) Downgraded to Strong Sell at Zacks Investment ResearchChromaDex (CDXC) Downgraded to Strong Sell at Zacks Investment Research
www.americanbankingnews.com - April 17 at 8:43 PM
Critical Survey: Stada Arzneimittel (STDAF) and ChromaDex (CDXC)Critical Survey: Stada Arzneimittel (STDAF) and ChromaDex (CDXC)
www.americanbankingnews.com - April 14 at 5:28 AM
Analyzing Stada Arzneimittel (STDAF) & ChromaDex (CDXC)Analyzing Stada Arzneimittel (STDAF) & ChromaDex (CDXC)
www.americanbankingnews.com - April 13 at 3:39 PM
TRU NIAGEN® to be featured at the American Academy of Anti-Aging Medicine Spring CongressTRU NIAGEN® to be featured at the American Academy of Anti-Aging Medicine Spring Congress
feeds.benzinga.com - April 5 at 7:55 AM
HC Wainwright Analysts Give ChromaDex (CDXC) a $8.00 Price TargetHC Wainwright Analysts Give ChromaDex (CDXC) a $8.00 Price Target
www.americanbankingnews.com - April 2 at 9:34 AM
Insider Selling: Chromadex Corp (CDXC) CEO Sells 24,578 Shares of StockInsider Selling: Chromadex Corp (CDXC) CEO Sells 24,578 Shares of Stock
www.americanbankingnews.com - March 29 at 10:46 PM
ChromaDex (CDXC) Announces Published Results from Human Clinical Study of NIAGENChromaDex (CDXC) Announces Published Results from Human Clinical Study of NIAGEN
www.streetinsider.com - March 29 at 9:49 AM
New Published Clinical Trial Confirms NIAGEN® Supplementation Raised Nicotinamide Adenine Dinucleotide (NAD) Levels and Potentially Improves Blood Pressure and Cardiovascular HealthNew Published Clinical Trial Confirms NIAGEN® Supplementation Raised Nicotinamide Adenine Dinucleotide (NAD) Levels and Potentially Improves Blood Pressure and Cardiovascular Health
finance.yahoo.com - March 29 at 9:49 AM
Chromadex (CDXC) Downgraded by BidaskClub to "Hold"Chromadex (CDXC) Downgraded by BidaskClub to "Hold"
www.americanbankingnews.com - March 28 at 12:34 AM
Head-To-Head Comparison: Anthera Pharmaceuticals (ANTH) & Chromadex (CDXC)Head-To-Head Comparison: Anthera Pharmaceuticals (ANTH) & Chromadex (CDXC)
www.americanbankingnews.com - March 20 at 3:34 AM
Chromadex (CDXC) Given a $8.00 Price Target at HC WainwrightChromadex (CDXC) Given a $8.00 Price Target at HC Wainwright
www.americanbankingnews.com - March 18 at 9:22 PM
Edited Transcript of CDXC earnings conference call or presentation 8-Mar-18 9:30pm GMTEdited Transcript of CDXC earnings conference call or presentation 8-Mar-18 9:30pm GMT
finance.yahoo.com - March 18 at 9:21 AM
Chromadex (CDXC) Downgraded by ValuEngine to "Sell"Chromadex (CDXC) Downgraded by ValuEngine to "Sell"
www.americanbankingnews.com - March 11 at 3:19 PM
Chromadex (CDXC) Rating Lowered to Sell at Zacks Investment ResearchChromadex (CDXC) Rating Lowered to Sell at Zacks Investment Research
www.americanbankingnews.com - March 9 at 7:30 PM
ChromaDexs (CDXC) CEO Frank Jaksch on Q4 2017 Results - Earnings Call Transcript - Seeking AlphaChromaDex's (CDXC) CEO Frank Jaksch on Q4 2017 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - March 9 at 9:58 AM
Chromadex (CDXC) Releases  Earnings Results, Misses Expectations By $0.14 EPSChromadex (CDXC) Releases Earnings Results, Misses Expectations By $0.14 EPS
www.americanbankingnews.com - March 9 at 12:38 AM
ChromaDex reports 4Q lossChromaDex reports 4Q loss
finance.yahoo.com - March 8 at 5:24 PM
ChromaDex Corporation Reports 2017 Financial Results   ChromaDex Corporation Reports 2017 Financial Results   
finance.yahoo.com - March 8 at 5:24 PM
ChromaDex to Present at the 30th Annual ROTH Conference on March 12, 2018ChromaDex to Present at the 30th Annual ROTH Conference on March 12, 2018
finance.yahoo.com - March 6 at 9:16 AM
Chromadex (CDXC) to Release Quarterly Earnings on ThursdayChromadex (CDXC) to Release Quarterly Earnings on Thursday
www.americanbankingnews.com - March 5 at 6:10 PM
Chromadex (CDXC) PT Set at $8.00 by HC WainwrightChromadex (CDXC) PT Set at $8.00 by HC Wainwright
www.americanbankingnews.com - March 5 at 2:58 PM
Tieton Capital Management LLC Trims Holdings in Chromadex Corp (CDXC)Tieton Capital Management LLC Trims Holdings in Chromadex Corp (CDXC)
www.americanbankingnews.com - February 27 at 4:14 PM
 Brokerages Anticipate Chromadex Corp (CDXC) to Announce -$0.01 Earnings Per Share Brokerages Anticipate Chromadex Corp (CDXC) to Announce -$0.01 Earnings Per Share
www.americanbankingnews.com - February 26 at 10:48 AM
Two Additional Collaborative Human Studies on NIAGEN® with the University of Cambridge and the University of Washington Now Registered on Clinical-trials.gov.Two Additional Collaborative Human Studies on NIAGEN® with the University of Cambridge and the University of Washington Now Registered on Clinical-trials.gov.
finance.yahoo.com - February 20 at 9:04 AM
BRIEF-Chromadex Chairman Stephen Allen Will Retire From The BoardBRIEF-Chromadex Chairman Stephen Allen Will Retire From The Board
www.reuters.com - February 17 at 8:58 AM
ChromaDex (CDXC) Chairman Stephen Allen to Retire from Board of DirectorsChromaDex (CDXC) Chairman Stephen Allen to Retire from Board of Directors
www.streetinsider.com - February 17 at 8:58 AM
ChromaDex Chairman Stephen Allen Will Retire from Board of DirectorsChromaDex Chairman Stephen Allen Will Retire from Board of Directors
finance.yahoo.com - February 16 at 4:37 PM
Chromadex (CDXC) Cut to Sell at Zacks Investment ResearchChromadex (CDXC) Cut to Sell at Zacks Investment Research
www.americanbankingnews.com - February 12 at 7:18 PM
ChromaDex (CDXC) Reports Prelim. 4Q Revenues Above Consensus, Prelim. FY18 Revenues Expected Below EstimatesChromaDex (CDXC) Reports Prelim. 4Q Revenues Above Consensus, Prelim. FY18 Revenues Expected Below Estimates
www.streetinsider.com - February 12 at 9:06 AM
ChromaDex Corporation Reports Preliminary 2017 Results   ChromaDex Corporation Reports Preliminary 2017 Results   
finance.yahoo.com - February 12 at 9:06 AM
Chromadex (CDXC) Upgraded at BidaskClubChromadex (CDXC) Upgraded at BidaskClub
www.americanbankingnews.com - February 11 at 9:36 AM
Chromadex (CDXC) Given a $8.00 Price Target by HC Wainwright AnalystsChromadex (CDXC) Given a $8.00 Price Target by HC Wainwright Analysts
www.americanbankingnews.com - February 10 at 4:44 PM
Chromadex (CDXC) Lifted to Hold at ValuEngineChromadex (CDXC) Lifted to Hold at ValuEngine
www.americanbankingnews.com - February 8 at 11:14 PM
National Institutes of Health (NIH) Announces NIAGEN® Prevents Neurological Damage and Shows Improved Cognitive and Physical Function in a Mouse Model of Alzheimer’s DiseaseNational Institutes of Health (NIH) Announces NIAGEN® Prevents Neurological Damage and Shows Improved Cognitive and Physical Function in a Mouse Model of Alzheimer’s Disease
finance.yahoo.com - February 8 at 8:53 AM
ChromaDex to Present at the 3rd Annual NAD+ SummitChromaDex to Present at the 3rd Annual NAD+ Summit
finance.yahoo.com - February 1 at 9:16 AM
Chromadex (CDXC) Lowered to "Sell" at BidaskClubChromadex (CDXC) Lowered to "Sell" at BidaskClub
www.americanbankingnews.com - January 27 at 3:58 PM
ChromaDex (CDXC) Reports Denial by PTAB of Elysium Healths Challenge of ChromaDex Licensed 807 Patent - StreetInsider.comChromaDex (CDXC) Reports Denial by PTAB of Elysium Health's Challenge of ChromaDex Licensed '807' Patent - StreetInsider.com
www.streetinsider.com - January 23 at 8:15 AM
ChromaDex Appoints Mark Friedman as General Counsel and Corporate Secretary - GlobeNewswire (press release)ChromaDex Appoints Mark Friedman as General Counsel and Corporate Secretary - GlobeNewswire (press release)
globenewswire.com - January 23 at 8:15 AM
ChromaDex Appoints Mark Friedman as General Counsel and Corporate SecretaryChromaDex Appoints Mark Friedman as General Counsel and Corporate Secretary
finance.yahoo.com - January 23 at 8:15 AM
BRIEF-Chromadex - Patent Trial And Appeal Board Of U.S. Patent And Trademark Office Denied Elysium Healths Request To Invalidate U.S. PatentBRIEF-Chromadex - Patent Trial And Appeal Board Of U.S. Patent And Trademark Office Denied Elysium Health's Request To Invalidate U.S. Patent
www.reuters.com - January 22 at 5:52 PM
Elysium Health, Inc. Challenge of ChromaDex Licensed Patent Denied by Patent Trial and Appeal Board (PTAB)Elysium Health, Inc. Challenge of ChromaDex Licensed Patent Denied by Patent Trial and Appeal Board (PTAB)
finance.yahoo.com - January 22 at 5:52 PM
Chromadexs (CDXC) Buy Rating Reiterated at HC WainwrightChromadex's (CDXC) Buy Rating Reiterated at HC Wainwright
www.americanbankingnews.com - January 16 at 8:08 AM
Head-To-Head Contrast: Portola Pharmaceuticals (PTLA) vs. Chromadex (CDXC)Head-To-Head Contrast: Portola Pharmaceuticals (PTLA) vs. Chromadex (CDXC)
www.americanbankingnews.com - January 13 at 5:06 PM
Insider Selling: Chromadex Corp (CDXC) CEO Sells 28,379 Shares of StockInsider Selling: Chromadex Corp (CDXC) CEO Sells 28,379 Shares of Stock
www.americanbankingnews.com - January 12 at 6:58 PM

SEC Filings

ChromaDex (NASDAQ:CDXC) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Financials are not available for this stock.

Chart

ChromaDex (NASDAQ CDXC) Stock Chart for Wednesday, April, 25, 2018

Loading chart…

This page was last updated on 4/25/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.